Evidence map›Paper›PMID 24152580›Full record

ArticleGene therapy2014

Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver.

P Maczuga, J Verheij, C van der Loos, R van Logtenstein, G Hooijer, R Martier, F Borel, J Lubelski, A Koornneef, B Blits and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Gene therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. AAV-mediated gene therapy for atherosclerosis.Current atherosclerosis reports · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

P Maczuga1] Department of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands [2] Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
J VerheijDepartment of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
C van der LoosDepartment of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
R van LogtensteinDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
G HooijerDepartment of Pathology, Academic Medical Center, Amsterdam, The Netherlands.
R MartierDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
F Borel1] Department of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands [2] Department of Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, The Netherlands.
J LubelskiDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
A KoornneefDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
B BlitsDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
S van DeventerDepartment of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands.
H PetryDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
P KonstantinovaDepartment of Research & Development, uniQure Biopharma B.V., Amsterdam, The Netherlands.
UniQure (Netherlands) · NLAcademic Medical Center · NLLeiden University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Constitutive expression of short hairpin RNAs (shRNAs) may cause cellular toxicity in vivo and using microRNA (miRNA) scaffolds can circumvent this problem. Previously, we have shown that embedding small interfering RNA sequences targeting apolipoprotein B100 (ApoB) in shRNA (shApoB) or miRNA (miApoB) scaffolds resulted in differential processing and long-term efficacy in vivo. Here we show that adeno-associated virus (AAV)-shApoB- or AAV-miApoB-mediated ApoB knockdown induced differential liver morphology and transcriptome expression changes. Our analyses indicate that ApoB knockdown with both shApoB and miApoB resulted in alterations of genes involved in lipid metabolism. In addition, in AAV-shApoB-injected animals, genes involved in immune system activation or cell growth and death were affected, which was associated with increased hepatocyte proliferation. Subsequently, in AAV-miApoB-injected animals, changes of genes involved in oxidoreductase activity, oxidative phosphorylation and nucleic bases biosynthetic processes were observed. Our results demonstrate that long-term knockdown of ApoB in vivo by shApoB or miApoB induces several transcriptome changes in murine liver. The increased hepatocyte profileration by AAV-shRNA may have severe long-term effects indicating that AAV-mediated RNA interference therapy using artificial miRNA may be a safer approach for familial hypercholesterolemia therapy.

Indexed as

Genetic VectorsAnimalsApolipoprotein B-100Cell DeathCell ProliferationDependovirusGene Expression ProfilingGene Knockdown TechniquesHepatocytesLipid MetabolismLiverMaleMiceMice, Inbred C57BLMicroRNAsPhenotypeApolipoprotein B-100MicroRNAsRNA, Small Interfering

Identifiers

PMID24152580
PMCPMC3881031
OpenAlexW2008094951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.